Jessica Prince Wolfish, MD
Ophthalmology · Southampton, PANPI 1801110366
Payments from drug & device makers
Across 100 payments — averaging $22.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Oyster Point Pharma, Inc.$404
- Novartis$312
- AbbVie$299
- Sun Pharmaceutical Industries Inc.$185
- Tarsus Pharmaceuticals, Inc.$149
- Bausch & Lomb Americas Inc.$124
- plus $752 from 15 others
What the payments were for
- Food & beverage$2,18998%
- Gifts$372%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Oyster Point Pharma, Inc. | 21 | $404 |
| Novartis | 14 | $312 |
| AbbVie(2 entities) | 10 | $299 |
| Sun Pharmaceutical Industries Inc. | 9 | $185 |
| Tarsus Pharmaceuticals, Inc. | 5 | $149 |
| Bausch & Lomb Americas Inc. | 6 | $124 |
| Harrow Eye, LLC | 5 | $109 |
| Ocular Therapeutix, Inc. | 5 | $97 |
| Biotissue Holdings Inc. | 4 | $96 |
| Alcon | 5 | $96 |
| Dompe US, Inc. | 2 | $68 |
| Amgen | 3 | $58 |
| Genentech USA, Inc. | 2 | $40 |
| Thea Pharma Inc. | 2 | $35 |
| Conmed Corporation | 1 | $28 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Mallinckrodt Hospital Products Inc. | 1 | $24 |
| Apellis Pharmaceuticals, Inc. | 1 | $23 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Carl Zeiss Meditec, Inc. | 1 | $17 |
| Aerie Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LUMIGAN$125
How this compares
$2,225 in reported general payments places this provider in the 60th percentile of 920 ophthalmology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OxervateCenegermin-Bkbj | 13 | $473,945 |
| RestasisCyclosporine | 95 | $107,189 |
| XiidraLifitegrast | 47 | $64,048 |
| Cyclosporine | 67 | $45,554 |
| LumiganBimatoprost | 76 | $35,770 |
| Prednisolone Acetate | 476 | $17,635 |
| TyrvayaVarenicline Tartrate | 21 | $13,299 |
| RhopressaNetarsudil Mesylate | 32 | $11,027 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $7,554 |
| MoxifloxacinMoxifloxacin Hcl | 419 | $7,233 |
| ZirganGanciclovir | 11 | $5,187 |
| Latanoprost | 324 | $4,200 |
| Ketorolac Tromethamine | 300 | $4,034 |
| ValacyclovirValacyclovir Hcl | 78 | $3,828 |
| ErythromycinErythromycin Base | 292 | $3,533 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Dompe US, Inc.Oxervate | $68 | $473,94513 claims |
| AbbVieRestasis, Lumigan | $299 | $142,959171 claims |
| Bausch & Lomb Americas Inc.Xiidra, Zirgan | $124 | $69,23558 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $404 | $13,29921 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $15 | $11,02732 claims |
| AlconSimbrinza | $96 | $7,55422 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 920 ophthalmology providers in Pennsylvania.
Other ophthalmology in Southampton
- David AlmeidaErie$6.3M
- William ChristieCranberry Township$5.2M
- Carl RegilloPlymouth Meeting$3.2M
- Erik KrugerKingston$3M
- Sunir GargPlymouth Meeting$2M
- Allen ChiangPlymouth Meeting$1.6M
- Julia HallerPhiladelphia$1.5M
- Mitchell FinemanPlymouth Meeting$1.3M
- Allen HoPlymouth Meeting$1.3M
- Brandon AyresBala Cynwyd$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.